Indivior Pharmaceuticals
INDV
113 hedge funds and large institutions have $975M invested in Indivior Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 23 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
70% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 23
17% more capital invested
Capital invested by funds: $834M → $975M (+$141M)
10% more funds holding
Funds holding: 103 → 113 (+10)
7.02% more ownership
Funds ownership: 54.97% → 62% (+7%)
2% more call options, than puts
Call options by funds: $831K | Put options by funds: $811K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$39M |
| 2 |
Goldman Sachs
New York
|
+$21.8M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$14M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$8.41M |
| 5 |
Citigroup
New York
|
+$7.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$21.6M |
| 2 |
Morgan Stanley
New York
|
-$17.2M |
| 3 |
Barclays
London,
United Kingdom
|
-$14M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$11.3M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$8.24M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Axa
Paris,
France
| – | -$167K | -17,118 | Closed |
|
|
GCM
127
Graham Capital Management
Rowayton,
Connecticut
| – | -$138K | -14,169 | Closed |
|
|
NS
128
NBC Securities
Birmingham,
Alabama
| – | -$4K | -470 | Closed |
|
|
CFO
129
CVA Family Office
Denver,
Colorado
| – | -$1.99K | -204 | Closed |
|
INDV Hedge Fund Activity: Q4 2024 in Review
113 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q4 2024, worth a combined $975M — up 17% from $834M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new INDV positions and 16 closed out — a net gain of 12 holders — while 39 added to existing stakes and 23 trimmed.
The largest buyer was Deerfield Management, adding an estimated $39M. The largest seller was Norges Bank, exiting entirely with an estimated $21.6M sold.
- 113 institutional investors held Indivior Pharmaceuticals (INDV) as of Q4 2024, up from 103 in Q3 2024.
- Funds reported $975M of Indivior Pharmaceuticals stock for Q4 2024, up 17% quarter-over-quarter.
- 28 funds opened new Indivior Pharmaceuticals positions in Q4 2024 and 16 closed out, a net change of +12 holders.
- The largest Indivior Pharmaceuticals buyer in Q4 2024 was Deerfield Management, an estimated $39M added.
- The largest Indivior Pharmaceuticals seller in Q4 2024 was Norges Bank, an estimated $21.6M sold.
Based on aggregated 13F filings for Q4 2024.